Barclays PLC Revance Therapeutics, Inc. Transaction History

Barclays PLC

  • $377 Billion
  • Q3 2024

A detailed history of Barclays PLC transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 173,355 shares of RVNC stock, worth $445,522. This represents 0.0% of its overall portfolio holdings.

Number of Shares
173,355
Previous 173,355 -0.0%
Holding current value
$445,522
Previous $900,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024
BUY
$2.57 - $2.57 $349,558 - $349,558
136,015 Added 364.26%
173,355 $900,000
Q2 2024

Aug 14, 2024
SELL
$2.34 - $4.73 $6.98 Million - $14.1 Million
-2,982,002 Reduced 98.76%
37,340 $95,000
Q1 2024

May 15, 2024
BUY
$4.65 - $9.31 $12.4 Million - $24.8 Million
2,661,786 Added 744.44%
3,019,342 $14.9 Million
Q4 2023

Feb 15, 2024
SELL
$5.81 - $11.2 $1.03 Million - $1.98 Million
-176,766 Reduced 33.08%
357,556 $3.14 Million
Q3 2023

Nov 07, 2023
BUY
$11.47 - $25.07 $2.91 Million - $6.36 Million
253,564 Added 90.31%
534,322 $6.13 Million
Q2 2023

Aug 03, 2023
BUY
$24.7 - $37.61 $69,728 - $106,173
2,823 Added 1.02%
280,758 $7.11 Million
Q1 2023

May 04, 2023
SELL
$18.36 - $35.27 $562,348 - $1.08 Million
-30,629 Reduced 9.93%
277,935 $8.95 Million
Q4 2022

Feb 13, 2023
BUY
$18.32 - $30.66 $3.93 Million - $6.58 Million
214,634 Added 228.5%
308,564 $5.7 Million
Q3 2022

Nov 03, 2022
BUY
$14.33 - $28.47 $698,214 - $1.39 Million
48,724 Added 107.78%
93,930 $2.54 Million
Q2 2022

Aug 12, 2022
BUY
$11.52 - $20.4 $285,580 - $505,715
24,790 Added 121.42%
45,206 $625,000
Q1 2022

May 16, 2022
SELL
$12.36 - $20.31 $1.09 Million - $1.8 Million
-88,519 Reduced 81.26%
20,416 $398,000
Q4 2021

Feb 14, 2022
BUY
$12.46 - $27.87 $832,963 - $1.86 Million
66,851 Added 158.85%
108,935 $1.78 Million
Q3 2021

Nov 09, 2021
BUY
$25.78 - $33.21 $381,183 - $491,043
14,786 Added 54.17%
42,084 $1.17 Million
Q2 2021

Aug 13, 2021
SELL
$26.8 - $31.84 $887,106 - $1.05 Million
-33,101 Reduced 54.8%
27,298 $809,000
Q1 2021

May 13, 2021
BUY
$24.03 - $29.97 $768,527 - $958,500
31,982 Added 112.55%
60,399 $1.69 Million
Q4 2020

Feb 11, 2021
SELL
$23.41 - $28.34 $134,490 - $162,813
-5,745 Reduced 16.82%
28,417 $805,000
Q3 2020

Nov 12, 2020
SELL
$23.23 - $34.3 $48,968 - $72,304
-2,108 Reduced 5.81%
34,162 $859,000
Q2 2020

Aug 12, 2020
BUY
$12.6 - $26.55 $177,156 - $373,293
14,060 Added 63.3%
36,270 $886,000
Q1 2020

May 13, 2020
SELL
$12.46 - $27.81 $411,391 - $918,202
-33,017 Reduced 59.78%
22,210 $329,000
Q4 2019

Feb 10, 2020
BUY
$11.66 - $20.15 $220,887 - $381,721
18,944 Added 52.21%
55,227 $896,000
Q3 2019

Nov 14, 2019
SELL
$10.22 - $14.5 $53,348 - $75,690
-5,220 Reduced 12.58%
36,283 $471,000
Q2 2019

Aug 14, 2019
BUY
$10.67 - $15.49 $85,637 - $124,322
8,026 Added 23.97%
41,503 $538,000
Q1 2019

May 15, 2019
BUY
$15.4 - $20.39 $265,804 - $351,931
17,260 Added 106.43%
33,477 $529,000
Q4 2018

Feb 14, 2019
SELL
$18.06 - $24.96 $201,928 - $279,077
-11,181 Reduced 40.81%
16,217 $326,000
Q3 2018

Nov 14, 2018
BUY
$23.55 - $30.1 $352,967 - $451,138
14,988 Added 120.77%
27,398 $682,000
Q2 2018

Aug 14, 2018
SELL
$27.45 - $33.35 $371,673 - $451,559
-13,540 Reduced 52.18%
12,410 $341,000
Q1 2018

May 15, 2018
BUY
$29.15 - $37.4 $198,628 - $254,843
6,814 Added 35.61%
25,950 $800,000
Q4 2017

Feb 14, 2018
BUY
$24.55 - $36.3 $182,087 - $269,237
7,417 Added 63.29%
19,136 $684,000
Q3 2017

Nov 14, 2017
BUY
$22.55 - $28.1 $264,263 - $329,303
11,719
11,719 $322,000

Others Institutions Holding RVNC

# of Institutions
234
Shares Held
82.8M
Call Options Held
680K
Put Options Held
896K
View Full List

About Revance Therapeutics, Inc.

RVNC Quotes by TradingView
  • Ticker RVNC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,305,696
  • Market Cap $212M
  • Description
  • Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...
More about RVNC
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email